March 27, 2023

Dubai Week

Complete Dubai News World

A drug creates a revolution .. and brings an end to two diseases in the human body

A drug creates a revolution .. and brings an end to two diseases in the human body

And the British newspaper, the Daily Mail, announced on Sunday that the directors of the National Health Service Britain The NHS granted the right to medication to about 91,000 patients in the country.

This approval came after a study found that daily intake of “toboglyphosine” reduces the risk of requiring medication. Dialysis Or cultivate up to 39 percent mortality.

This drug is the first major development in the treatment of kidney disease in about 20 years.

The “Daily Mail” says that 30,000 people in the UK need dialysis, which removes waste and excess fluid from the body.

Doctors seek this out when the kidneys are unable to do their part in filtering the waste well.

Severe pain caused by dialysis operations The patient undergoes intensive dialysis sessions 3 times a week at the hospital.

“This drug represents a new and exciting opportunity for patients,” says Graham Lipkin, British physician and general secretary of the Society for Kidney Care in the UK.

Lipkin added that the new drug would slow the progression of the disease, which is expected to reduce the number of patients requiring dialysis or kidney transplant surgery.

There is no cure for kidney disease yet, but doctors recommend adjusting your lifestyle, maintaining a healthy weight, eating less salt, and exercising regularly.

The problem with kidney disease is that over time it leads to the destruction of the heart, and heart failure is usually the leading cause of death for people with this disease.

Toboglyphosine, trademark “Forxiga”, belongs to the group of drugs used to remove excess glucose from the blood of diabetics.

See also  An event that threatens life on earth .. This is what happens inside the sun

Researchers have found that these drugs can help improve kidney function in people who do not have diabetes.

The results of clinical trials of about 5,000 people and published in the New England Journal of Medicine show that many patients have benefited from the drug.